drug
buprenorphine LA
Marketedupdated 5mo agoby $INDV Indivior Pharmaceuticals, Inc.
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 6Small molecule drug with a maximum clinical stage of Approval (across all indications), with 7 approved and 23 investigational indications.
all catalysts(25)
approval · 25
Nov 30, 2017
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Mar 5, 2018
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Oct 7, 2019
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Feb 4, 2020
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Jun 15, 2020
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Mar 4, 2021
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
May 11, 2021
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Jun 17, 2021
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Sep 22, 2021
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Jun 17, 2022
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Aug 23, 2022
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Jan 6, 2023
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Mar 13, 2023
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
May 23, 2023
approval
BRIXADI (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Jul 3, 2023
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Sep 12, 2023
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Dec 15, 2023
approval
BRIXADI (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Dec 15, 2023
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Apr 19, 2024
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Feb 21, 2025
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Mar 28, 2025
approval
BRIXADI (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Apr 11, 2025
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Aug 29, 2025
approval
BRIXADI (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Dec 22, 2025
approval
$INDV35.71+0.93%
SUBLOCADE (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Dec 22, 2025
approval
BRIXADI (BUPRENORPHINE) — FDA approval
buprenorphine LA
→
Trials studying buprenorphine LA
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 10, 2027
98 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (79)
- Jun 22, 2038method-of-use (U-2489)US 10646484
- Nov 6, 2035method-of-use (U-3111)US 11000520
- Nov 6, 2035method-of-use (U-3111)US 11000520
- Nov 6, 2035method-of-use (U-3111)US 11839611
- Nov 6, 2035method-of-use (U-3111)US 11839611
- Jul 26, 2032method-of-use (U-3617)US 10912772
- Jul 26, 2032method-of-use (U-3617)US 10912772
- Jul 26, 2032method-of-use (U-3617)US 10912772
- Jul 26, 2032method-of-use (U-3617)US 10912772
- Jul 26, 2032method-of-use (U-3617)US 10912772
- Jul 26, 2032method-of-use (U-3617)US 10912772
- Jul 26, 2032method-of-use (U-3617)US 10912772
- Jul 26, 2032formulationUS 11110084
- Jul 26, 2032formulationUS 11110084
- Jul 26, 2032formulationUS 11110084
- Jul 26, 2032formulationUS 11110084
- Jul 26, 2032formulationUS 11110084
- Jul 26, 2032formulationUS 11110084
- Jul 26, 2032formulationUS 11110084
- Jul 26, 2032formulationUS 11135215
- Jul 26, 2032formulationUS 11135215
- Jul 26, 2032formulationUS 11135215
- Jul 26, 2032formulationUS 11135215
- Jul 26, 2032formulationUS 11135215
- Jul 26, 2032formulationUS 11135215
- Jul 26, 2032formulationUS 11135215
- Jul 26, 2032formulationUS 12161640
- Jul 26, 2032formulationUS 12161640
- Jul 26, 2032formulationUS 12161640
- Jul 26, 2032formulationUS 12161640
- Jul 26, 2032formulationUS 12161640
- Jul 26, 2032formulationUS 12161640
- Jul 26, 2032formulationUS 12161640
- Jul 26, 2032formulationUS 12318379
- Jul 26, 2032formulationUS 12318379
- Jul 26, 2032formulationUS 12318379
- Jul 26, 2032formulationUS 12318379
- Jul 26, 2032formulationUS 12318379
- Jul 26, 2032formulationUS 12318379
- Jul 26, 2032formulationUS 12318379
- Jul 26, 2032formulationUS 9937164
- Jul 26, 2032formulationUS 9937164
- Jul 26, 2032formulationUS 9937164
- Jul 26, 2032formulationUS 9937164
- Jul 26, 2032formulationUS 9937164
- Jul 26, 2032formulationUS 9937164
- Jul 26, 2032formulationUS 9937164
- Jan 6, 2032formulationUS 8921387
- Jan 6, 2032formulationUS 8921387
- Sep 5, 2031formulationUS 89752704.9y
- Sep 5, 2031formulationUS 89752704.9y
- Jun 25, 2031formulationUS 105583944.7y
- Jun 25, 2031formulationUS 105583944.7y
- Jun 6, 2031method-of-use (U-2489)US 101982184.7y
- Jun 6, 2031method-of-use (U-2489)US 101982184.7y
- Jun 6, 2031method-of-use (U-2489)US 105921684.7y
- Jun 6, 2031method-of-use (U-2489)US 105921684.7y
- Jun 6, 2031method-of-use (U-2177)US 92720444.7y
- Jun 6, 2031method-of-use (U-2177)US 92720444.7y
- Jun 6, 2031formulationUS 94984324.7y
- Jun 6, 2031formulationUS 94984324.7y
- Jun 6, 2031formulationUS 97824024.7y
- Jun 6, 2031formulationUS 97824024.7y
- Jun 6, 2031formulationUS 98272414.7y
- Jun 6, 2031formulationUS 98272414.7y
- Jan 10, 2027formulationUS 823629298d
- Jan 10, 2027formulationUS 823629298d
- Jan 10, 2027formulationUS 823629298d
- Jan 10, 2027formulationUS 823629298d
- Jan 10, 2027formulationUS 823629298d
- Jan 10, 2027formulationUS 823629298d
- Jan 10, 2027formulationUS 823629298d
- Jul 31, 2026formulationUS 8236755
- Jul 31, 2026formulationUS 8236755
- Jul 31, 2026formulationUS 8236755
- Jul 31, 2026formulationUS 8236755
- Jul 31, 2026formulationUS 8236755
- Jul 31, 2026formulationUS 8236755
- Jul 31, 2026formulationUS 8236755
FDA exclusivities (9)
- Feb 21, 2028M-314Method (3y)1.4y
- Feb 21, 2028M-314Method (3y)1.4y
- May 23, 2026NPNP
- May 23, 2026NPNP
- May 23, 2026NPNP
- May 23, 2026NPNP
- May 23, 2026NPNP
- May 23, 2026NPNP
- May 23, 2026NPNP
News(3)
- Indivior ends PAM drug collab with Addex ahead of Supernus mergerAhead of its upcoming merger with Supernus, Indivior Pharmaceuticals has ended its long-running collaboration with Addex Therapeutics to develop positive allosteric modulators (PAMs).fiercebiotech · 8d ago
- Supernus and Indivior merge to create CNS mega-company with 11 approved drugsSupernus Pharmaceuticals and Indivior Pharmaceuticals are outlining a combined expected $2.2 billion in annual revenue, plus $125 million in cost savings that will include “natural redundancies.”biospace · 2mo ago
- Supernus, Indivior merge to beef up brain drug portfolioThe transaction combines two companies marketing nearly a dozen neurological drugs that bring in steady, but not blockbuster sales for conditions such as opioid use disorder and Parkinson's.biopharma_dive · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that